Bronchiectasis is a disease defined by a permanent and usually progressive bronchial dilation associated with multiple exacerbations and decreased health-related quality of life [1] [2] [3] . Improvement in the current knowledge of this condition's pathophysiology has clearly highlighted its complex and heterogeneous profile, whose severity or prognosis cannot be defined using a single variable [4] . Accordingly, multidimensional scores including demographical, clinical, microbiological and radiological data have recently been developed and validated as useful tools to better evaluate the disease's severity and prognosis: FACED (forced expiratory volume in 1 s (FEV1), age, chronic colonisation by Pseudomonas aeruginosa, radiological extension and dyspnoea), E-FACED (FACED plus exacerbations) and the bronchiectasis severity index (BSI) [5] [6] [7] [8] .
1.62±1.8, and the number of hospitalisations was 0.56±1.1. Chronic bronchial infection by P. aeruginosa was identified in 27.5% of the patients. Mean FACED and E-FACED scores were 2.36±1.8 and 3.02±2.23, respectively. According to the FACED and E-FACED scores, 56.6% and 61.5% of patients presented mild bronchiectasis; 29.5% and 30% moderate bronchiectasis and 13.8% and 8.6% severe bronchiectasis, respectively. The cumulative mortality was as follows. First year: 37 (2.5%) patients; second year: 72 (4.9%) patients; third year: 129 (8.8%) patients; fourth year 184 (12.5%) patients; and fifth year 249 (16.9%) patients. Figure 1 presents annual AUC ROC for FACED (range 0.77-0.83) and E-FACED scores (range 0.79-0.84) during the 5-year follow-up period. There were no statistical differences between the yearly predictive power of BSI compared with FACED/E-FACED scores. The range value of AUC ROC for BSI (0.79-0.82) was very similar to the range value for FACED (0.77-0.83) and E-FACED (0.79-0.84). Moreover, bronchiectasis classified as mild by FACED or E-FACED presented a decreased yearly mortality risk compared with those categorised as moderate and severe, as assessed by the log rank (Mantel-Cox) test. The results were similar for both scores and for every year. The differences between groups were more evident from the third year, due to the increasing number of accumulated deaths.
Our study shows that both FACED and E-FACED scores maintained an excellent predictive power for all-cause mortality, even in shorter periods of time than originally described [5] [6] [7] . We analysed data from a large cohort of patients, who were well-characterised using standardised protocols in specialised outpatient clinics. Mortality results were similar in all the participating centres, even though the patients presented very different clinical characteristics and underlying aetiologies of bronchiectasis.
FACED and E-FACED scores are easy to remember and to apply, and have proved useful for predicting mid-and long-term mortality in different cohorts from several countries [5] [6] [7] 9] . The results of our study show that they may also be useful, in the same way as the BSI score, for predictions of short-term mortality. This prognostic ability could improve bronchiectasis management in both daily practice and clinical trial scenarios. In daily practice, this short-term prognosis may help to identify patients who need more intensive or preventive treatments, such as chronic antibiotics or anti-inflammatory agents, and to develop personalised management strategies that allow an individualised approach. New guidelines that standardise bronchiectasis management based on the best available evidence may help decision making of when to apply treatments of higher or lower intensity, depending on the multidimensional severity of the disease and its expected mortality [11, 12] . As regards the clinical trials scenario, we believe that these scores may play an important role in identifying a more precise population that could benefit from specific interventions based on a shorter or longer expected mechanism of action [13] .
One strength of this study is the large number of patients included from very different settings with a well-characterised baseline profile. Although all the clinical variables used to establish both scores were recorded as near as possible to the diagnosis of bronchiectasis, one potential limitation of this study is that the treatments administered over the 5 years of follow-up could have influenced the mortality results. However, no medical treatment for bronchiectasis has yet been proven to reduce short-or long-term mortality. Another limitation is that we could not assess the possible role of comorbidities in mortality risk, as we did not have enough data to permit the calculation of the Charlson index or the bronchiectasis aetiology comorbidity index [14] .
In conclusion, FACED and E-FACED scores have been shown to be useful to predict all-cause mortality, not only in the long term, but also for short-term follow-up (yearly from the first to the fifth year after diagnosis). Further studies should validate our results in different populations of patients with bronchiectasis, evaluate whether the two scores are able to predict exacerbations and other key outcomes in short-term periods and assess which variables could influence the prognostic capacity of these scores over time, as well as to evaluate both scores' sensitivity to change after therapeutic interventions. 
